Targeting phosphatidylserine with calcium-dependent protein-drug conjugates for the treatment of cancer
Targeting phosphatidylserine with calcium-dependent protein-drug conjugates for the treatment of cancer
In response to cellular stress, phosphatidylserine is exposed on the outer membrane leaflet of tumor blood vessels and cancer cells, motivating the development of phosphatidylserine-specific therapies. The generation of drug-conjugated phosphatidylserine-targeting agents represents an unexplored therapeutic approach, for which antitumor effects are critically dependent on efficient internalization and lysosomal delivery of the cytotoxic drug. In the current study, we have generated phosphatidylserine-targeting agents by fusing phosphatidylserine-binding domains to a human IgG1-derived Fc fragment. The tumor localization and pharmacokinetics of several phosphatidylserine-specific Fc fusions have been analyzed in mice and demonstrate that Fc-Syt1, a fusion containing the synaptotagmin 1 C2A domain, effectively targets tumor tissue. Conjugation of Fc-Syt1 to the cytotoxic drug monomethyl auristatin E results in a protein-drug conjugate (PDC) that is internalized into target cells and, due to the Ca2+ dependence of phosphatidylserine binding, dissociates from phosphatidylserine in early endosomes. The released PDC is efficiently delivered to lysosomes and has potent antitumor effects in mouse xenograft tumor models. Interestingly, although an engineered, tetravalent Fc-Syt1 fusion shows increased binding to target cells, this higher avidity variant demonstrates reduced persistence and therapeutic effects compared with bivalent Fc-Syt1. Collectively, these studies show that finely tuned, Ca2+-switched phosphatidylserine-targeting agents can be therapeutically efficacious.
169-182
Li, Ran
3cdff050-f515-4bf6-8e53-76f78fbdc7ad
Chiguru, Srinivas
bb584e20-9bfb-4403-970f-18eefa85b79d
Li, Li
70ecb091-bb1f-45bf-86b6-17c87c70d210
Kim, Dongyoung
43a73b5c-3f2e-4ba9-8ffa-a7b454e2fd9f
Velmurugan, Ramraj
4f2d41cd-90eb-4f61-b5e0-df6308726d28
Kim, David
100bc2ff-304a-44c7-abea-8fc90ff78bfc
Devanaboyina, Siva Charan
4a79edaf-305f-4413-88b2-946e6284f98e
Tian, Hong
c92cce3a-fd28-46f5-b2d0-fa87d1d30b78
Schroit, Alan
a17bf22a-b8d2-48a2-8758-4c98ef5dd5d6
Mason, Ralph P.
e2909e92-8c39-4d5d-be1b-cfb9005e7b57
Ober, Raimund J.
31f4d47f-fb49-44f5-8ff6-87fc4aff3d36
Ward, E. Sally
b31c0877-8abe-485f-b800-244a9d3cd6cc
1 January 2018
Li, Ran
3cdff050-f515-4bf6-8e53-76f78fbdc7ad
Chiguru, Srinivas
bb584e20-9bfb-4403-970f-18eefa85b79d
Li, Li
70ecb091-bb1f-45bf-86b6-17c87c70d210
Kim, Dongyoung
43a73b5c-3f2e-4ba9-8ffa-a7b454e2fd9f
Velmurugan, Ramraj
4f2d41cd-90eb-4f61-b5e0-df6308726d28
Kim, David
100bc2ff-304a-44c7-abea-8fc90ff78bfc
Devanaboyina, Siva Charan
4a79edaf-305f-4413-88b2-946e6284f98e
Tian, Hong
c92cce3a-fd28-46f5-b2d0-fa87d1d30b78
Schroit, Alan
a17bf22a-b8d2-48a2-8758-4c98ef5dd5d6
Mason, Ralph P.
e2909e92-8c39-4d5d-be1b-cfb9005e7b57
Ober, Raimund J.
31f4d47f-fb49-44f5-8ff6-87fc4aff3d36
Ward, E. Sally
b31c0877-8abe-485f-b800-244a9d3cd6cc
Li, Ran, Chiguru, Srinivas, Li, Li, Kim, Dongyoung, Velmurugan, Ramraj, Kim, David, Devanaboyina, Siva Charan, Tian, Hong, Schroit, Alan, Mason, Ralph P., Ober, Raimund J. and Ward, E. Sally
(2018)
Targeting phosphatidylserine with calcium-dependent protein-drug conjugates for the treatment of cancer.
Molecular Cancer Therapeutics, 17 (1), .
(doi:10.1158/1535-7163.MCT-17-0092).
Abstract
In response to cellular stress, phosphatidylserine is exposed on the outer membrane leaflet of tumor blood vessels and cancer cells, motivating the development of phosphatidylserine-specific therapies. The generation of drug-conjugated phosphatidylserine-targeting agents represents an unexplored therapeutic approach, for which antitumor effects are critically dependent on efficient internalization and lysosomal delivery of the cytotoxic drug. In the current study, we have generated phosphatidylserine-targeting agents by fusing phosphatidylserine-binding domains to a human IgG1-derived Fc fragment. The tumor localization and pharmacokinetics of several phosphatidylserine-specific Fc fusions have been analyzed in mice and demonstrate that Fc-Syt1, a fusion containing the synaptotagmin 1 C2A domain, effectively targets tumor tissue. Conjugation of Fc-Syt1 to the cytotoxic drug monomethyl auristatin E results in a protein-drug conjugate (PDC) that is internalized into target cells and, due to the Ca2+ dependence of phosphatidylserine binding, dissociates from phosphatidylserine in early endosomes. The released PDC is efficiently delivered to lysosomes and has potent antitumor effects in mouse xenograft tumor models. Interestingly, although an engineered, tetravalent Fc-Syt1 fusion shows increased binding to target cells, this higher avidity variant demonstrates reduced persistence and therapeutic effects compared with bivalent Fc-Syt1. Collectively, these studies show that finely tuned, Ca2+-switched phosphatidylserine-targeting agents can be therapeutically efficacious.
This record has no associated files available for download.
More information
Accepted/In Press date: 29 August 2017
e-pub ahead of print date: 29 August 2017
Published date: 1 January 2018
Identifiers
Local EPrints ID: 423683
URI: http://eprints.soton.ac.uk/id/eprint/423683
ISSN: 1535-7163
PURE UUID: 892e863c-61e8-40c5-98b6-ab7597da8b1f
Catalogue record
Date deposited: 27 Sep 2018 16:30
Last modified: 16 Mar 2024 04:37
Export record
Altmetrics
Contributors
Author:
Ran Li
Author:
Srinivas Chiguru
Author:
Li Li
Author:
Dongyoung Kim
Author:
Ramraj Velmurugan
Author:
David Kim
Author:
Siva Charan Devanaboyina
Author:
Hong Tian
Author:
Alan Schroit
Author:
Ralph P. Mason
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics